1,172 results on '"Pommier Y"'
Search Results
2. Crystal structure of TDP1 complexed with compound XZ768
3. Preclinical Models of Neuroendocrine Neoplasia
4. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
5. Interaction of DNA topoisomerase 1 with DNA intermediates and proteins of base excision repair
6. Structure of Tdp1 catalytic domain in complex with inhibitor XZ634p
7. OA11.05 Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer
8. Dose–response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686288)
9. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine
10. 37P The CellMiner and CellMinerCDB web-applications as a base for pharmacogenomics
11. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases
12. 37P Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications
13. Sers and Fluorescence Study of the Molecular Interactions of Camptothecins with DNA and DNA Topoisomerase I and in their Ternary Cleavable Complexes
14. Raman, FT-Raman, Sers, and Circular Dichroism Studies of Structure-Activity Relationship of Topoisomerase Inhibition by Camptothecin Derivatives
15. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm
16. Crystal structure of Tdp1 catalytic domain in complex with compound XZ572
17. MA12.03 PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells
18. Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound PH004941
19. Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound CDS010292
20. Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment benzene-1,2,4-tricarboxylic acid from single soak
21. Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT1982 (single soak)
22. Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT0911 from cocktail soak
23. Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications
24. Erratum: CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
25. Meet Our Editorial Board Member
26. CellMiner and CellMiner cross-database (CDB): Resources for the exploration of pharmacogenomics using cancerous cell-lines
27. Development of novel indole-based tdp1 inhibitors for anticancer therapy
28. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
29. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
30. Induction of a novel long antisense RNA from the human HIF-1a locus may contribuite to HIF 1a regulation and inhibition by campotecin in cancer cells
31. DNA topoisomerase I (Top1) can regulate the coupling of RNA polymerase II (RNAP) pausing at promoter-proximal sites and transcript maturation in human cells
32. Docking Studies on Bifunctional Quinolinyl Diketo Acids as HIV-1 Integrase Inhibitors
33. 110P - CellMiner and CellMiner cross-database (CDB): Resources for the exploration of pharmacogenomics using cancerous cell-lines
34. Interaction between mianserin and clonidine at α 2-Adrenoceptors
35. Effects of some α-adrenoceptor agonists and antagonists on the guinea-pig ileum
36. Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin Topoisomerase I (top1) inhibitors
37. Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations
38. Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
39. SAR Studies on Quinolinyl-2,4-Dioxobutanoic Acids, HIV-1 Integrase Inhibitors that Block HIV-1 Replication in Infected Cells
40. Docking Studies on Bifunctional Quinolinyl Diketo Acids as HIV-1 Integrase Ihnhibitors
41. Quinolinyl-2,4-dioxobutanoic Acids as HIV-1 Integrase Inhibitors: SAR Studies and Binding Mode
42. Preparation of quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and aids related complex (ARC)
43. Sintesi, saggi enzimatici e attività antivirale di nuovi inibitori dell’integrasi di HIV
44. Molecular Interaction Maps - A Diagrammatic Graphical Language for Bioregulatory Networks
45. 248 Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongation
46. 252 The DNA damage response gene Schlafen 11 (SLFN11) is a transcriptional target of ETS transcription factors in Ewing's sarcoma and other cancers
47. A screen for the identification of inhibitors of tyrosyl-DNA phosphodiesterase 1
48. Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases II and II in vertebrate mitochondria
49. Investigation of anti-HIV activity, cytotoxicity and HIV integrase inhibitory activity of polyherbal formulation BH extracts
50. Repair of and checkpoint response to topoisomerase I-mediated DNA damage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.